issue 1 2017

analysis & control 61
of bowel movements (stool
frequency and consistency) in 579
healthy volunteers suffering from
IBS according to Rome III criteria. 5
The meta-analysis confirmed that
volunteers of the overall
population consuming ibSium ® felt
12.3% less pain/gastrointestinal
discomfort (p=0.01) than the one
consuming the placebo, which is
above the 10% minimum threshold
considered by the scientific
experts as clinically relevant. In the
IBS-C 6 subpopulation, volunteers
in the active group felt 12.3% less
bloated (p=0.04) compared to the
placebo group. In this
subpopulation, stool consistency in
the ibSium ® group was
significantly higher and classified
as normal compared to the
placebo group (p=0.0003) at the
end of the supplementation period.
These results confirm the
beneficial effect of ibSium ®
previously observed in both clinical
trials.
“Beyond the scientifically vetted
proof of efficacy it provides, this
new official publication is a
recognition of the company’s longterm
investment in providing
strong scientific and clinical data
to substantiate the health benefits
of its patented ingredient:
ibSium ® ,” states Elodie Ruffin,
Product Manager for Probiotics at
Lesaffre Human Care.
“Approximately a third of the
world’s population (roughly 2.4
billion people) is complaining
about some gut-related
symptoms. 7 In this context, it is
our responsibility, as one of the
major companies in the human
care segment, to contribute to
improving the quality of life of
these people by providing a
natural alternative proven to help
ease gastrointestinal symptoms,”
she explains.
ibSium ® can be considered as an
innovative strategy to improve the
quality of life in people suffering
from digestive disorders, such as
IBS subjects. Approved by
consumers through a large-scale
study run by prescribing physicians
in over 1160 volunteers presenting
symptoms of IBS, ibSium ® has
proven to be safe, fast-acting (less
than 15 days) and well-tolerated,
inducing no side-effects or
habituation. Based on the solid
scientifical and clinical evidence
available, ibSium ® also benefits
from a health claim granted by
Health Canada in 2015. 8 n
Lesaffre Human Care
www.lesaffrehumancare.com
1 Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in
irritable bowel syndrome: an individual subject meta-analysis. World J Gastroenterol 2017;23(2):336-344.
2 Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pélerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo
in the irritable bowel syndrome. Digestive and Liver Disease; 2015 February; 47(2):119-124
3 Spiller RS, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, Justen P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae
CNCM I-3856 in Irritable Bowel Syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology
Journal, DOI: 10.1177/2050640615602571.
4 European Food Safety Agency (EFSA). Guidance for claims on the immune system, GI tract and defence against pathogens. January 18, 2016.
5 Rome III Diagnostic criteria definition:
Recurrent abdominal pain or digestive discomfort for at least 3 days each month over the past 3 months,
Combined with at least 2 of the following: Improvement following bowel movement, Onset associated with a change in stool frequency
Onset associated with a change in stool consistency, Onset of symptoms at least 6 months prior to diagnosis
6 IBS-C patients suffer from IBS with constipation
7 World Gastroenterology Organisation (WGO). WGO Handbook on Diet and Gut Health
8 “Helps to reduce abdominal pain and discomfort associated with Irritable Bowel Syndrome (IBS)”
reprints
www.foodmagazine.eu.com
IF YOU ARE INTERESTED IN HAVING REPRINTS OF YOUR ARTICLE TO HAND OUT TO
YOUR CUSTOMERS/ PROSPECTS
please contact: john@foodmagazine.eu.com
IT’S A LOT LESS EXPENSIVE THAN YOU MIGHT THINK
www.foodmagazine.eu.com issue one | 2017